Cargando…
Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study
The antibiotic spectrum is not reflected in conventional antimicrobial metrics. Days of antibiotic spectrum coverage (DASC) is a novel quantitative metric for antimicrobial consumption developed with consideration of the antibiotic spectrum. However, there were no data regarding disease and pathogen...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774691/ https://www.ncbi.nlm.nih.gov/pubmed/36551402 http://dx.doi.org/10.3390/antibiotics11121745 |
_version_ | 1784855470008172544 |
---|---|
author | Maeda, Masayuki Nakata, Mari Naito, Yuika Yamaguchi, Kozue Yamada, Kaho Kinase, Ryoko Takuma, Takahiro On, Rintaro Tokimatsu, Issei |
author_facet | Maeda, Masayuki Nakata, Mari Naito, Yuika Yamaguchi, Kozue Yamada, Kaho Kinase, Ryoko Takuma, Takahiro On, Rintaro Tokimatsu, Issei |
author_sort | Maeda, Masayuki |
collection | PubMed |
description | The antibiotic spectrum is not reflected in conventional antimicrobial metrics. Days of antibiotic spectrum coverage (DASC) is a novel quantitative metric for antimicrobial consumption developed with consideration of the antibiotic spectrum. However, there were no data regarding disease and pathogen-specific DASC. Thus, this study aimed to evaluate the DASC trend in patients with bloodstream infections (BSIs). DASC and days of therapy (DOT) of in-patients with positive blood culture results during a 2-year interval were evaluated. Data were aggregated to calculate the DASC, DOT, and DASC/DOT per patient stratified by pathogens. During the 2-year study period, 1443 positive blood culture cases were identified, including 265 suspected cases of contamination. The overall DASC, DASC/patient, DOT, DOT/patient, and DASC/DOT metrics were 226,626; 157.1; 28,778; 19.9; and 7.9, respectively. A strong correlation was observed between DASC and DOT, as well as DASC/patient and DOT/patient. Conversely, DASC/DOT had no correlation with other metrics. The combination of DASC and DOT would be a useful benchmark for the overuse and misuse evaluation of antimicrobial therapy in BSIs. Notably, DASC/DOT would be a robust metric to evaluate the antibiotic spectrum that was selected for patients with BSIs. |
format | Online Article Text |
id | pubmed-9774691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97746912022-12-23 Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study Maeda, Masayuki Nakata, Mari Naito, Yuika Yamaguchi, Kozue Yamada, Kaho Kinase, Ryoko Takuma, Takahiro On, Rintaro Tokimatsu, Issei Antibiotics (Basel) Article The antibiotic spectrum is not reflected in conventional antimicrobial metrics. Days of antibiotic spectrum coverage (DASC) is a novel quantitative metric for antimicrobial consumption developed with consideration of the antibiotic spectrum. However, there were no data regarding disease and pathogen-specific DASC. Thus, this study aimed to evaluate the DASC trend in patients with bloodstream infections (BSIs). DASC and days of therapy (DOT) of in-patients with positive blood culture results during a 2-year interval were evaluated. Data were aggregated to calculate the DASC, DOT, and DASC/DOT per patient stratified by pathogens. During the 2-year study period, 1443 positive blood culture cases were identified, including 265 suspected cases of contamination. The overall DASC, DASC/patient, DOT, DOT/patient, and DASC/DOT metrics were 226,626; 157.1; 28,778; 19.9; and 7.9, respectively. A strong correlation was observed between DASC and DOT, as well as DASC/patient and DOT/patient. Conversely, DASC/DOT had no correlation with other metrics. The combination of DASC and DOT would be a useful benchmark for the overuse and misuse evaluation of antimicrobial therapy in BSIs. Notably, DASC/DOT would be a robust metric to evaluate the antibiotic spectrum that was selected for patients with BSIs. MDPI 2022-12-02 /pmc/articles/PMC9774691/ /pubmed/36551402 http://dx.doi.org/10.3390/antibiotics11121745 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Maeda, Masayuki Nakata, Mari Naito, Yuika Yamaguchi, Kozue Yamada, Kaho Kinase, Ryoko Takuma, Takahiro On, Rintaro Tokimatsu, Issei Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study |
title | Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study |
title_full | Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study |
title_fullStr | Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study |
title_full_unstemmed | Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study |
title_short | Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study |
title_sort | days of antibiotic spectrum coverage trends and assessment in patients with bloodstream infections: a japanese university hospital pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774691/ https://www.ncbi.nlm.nih.gov/pubmed/36551402 http://dx.doi.org/10.3390/antibiotics11121745 |
work_keys_str_mv | AT maedamasayuki daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy AT nakatamari daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy AT naitoyuika daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy AT yamaguchikozue daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy AT yamadakaho daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy AT kinaseryoko daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy AT takumatakahiro daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy AT onrintaro daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy AT tokimatsuissei daysofantibioticspectrumcoveragetrendsandassessmentinpatientswithbloodstreaminfectionsajapaneseuniversityhospitalpilotstudy |